[Effects of preoperative transcatheter hepatic arterial chemoembolization (TAE) on the prognosis of patients with hepatic carcinoma undergoing tumor resection].
This study consists of 77 hepatocellular carcinoma patients. Twenty-six (Group A) received preoperative TAE and 51 did not (Group B). Group A and B were further divided into two subgroups according to their tumor size i.e. Group A1 and B1 (tumor size 3-8 cm); Group A2 and B2 (tumor size > 8 cm). The 1-, 2-, 3-year disease free survival rates were 50.0%, 33.3%, 16.6% for Group A1 and 72.7%, 54.2%, 39.7% for Group B1; 75.0%, 56.2%, 45.0% for Group A2 and 38.9%, 32.4%, 10.8% for Group B2 respectively. The 1-, 3-, 5-years survival rates were 85.7%, 31.2%, 0 for Group A1 and 84.8%, 58.7%, 27.9% for Group B1; 91.6%, 82.5%, 53.0% for Group A2 and 77.8%, 30.1%, 0 for Group B2 respectively. There were significant differences between Group A2 and B2 both in disease free survival rate and 5-year survival rate (P < 0.05). The results also demonstrated that the preoperative TAE did worsen the prognosis of patients with tumor size between 3-8 cm (Group A1) with disease free survival rate and 5-year survival rate shorter than that of Group A2.
Lu
C
C
Department of Surgery, Second Affiliated Hospital, Zhejiang Medical University, Hangzhou.
Peng
S
S
Jiang
X
X
D000970:Antineoplastic Agents / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D005260:Female; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011300:Preoperative Care; D012189:Retrospective Studies; D015996:Survival Rate
D000970:Antineoplastic Agents